Renal Business Today

Sanofi-Aventis

Sanofi Names New CEO of Genzyme

PARIS—Sanofi has named David Meeker as Chief Executive Officer of Genzyme, a Sanofi company, effective November 1. ...More
October 24, 2011
Posted in News, Business
Sanofi-Aventis Releases New Ferrlecit Formulation

BRIDGEWATER, N.J.—In response to customer feedback, sanofi-aventis has started to sell its iron drug Ferrlecit in a new vial formulation, which is replacing the older ampule version in order to avoid and potential safety issues. ...More
April 22, 2011 By Keith Chartier
Posted in Articles, Business, Clinical & Pharma, Government & Regulation, Practice Management
Sanofi Aventis Acquires Genzyme for $20.1 Billion

CAMBRIDGE, Mass.—Sanofi-aventis will acquire Genzyme Corp. for $74 per share in cash, or approximately $20.1 billion, according to a Feb. 16 news release. ...More
February 16, 2011
Posted in News, Business, Government & Regulation
Genzyme Board Rejects Sanofi Aventis Offer

CAMBRIDGE, Mass.—Genzyme Corp. said Oct. 7 that its board of directors has voted unanimously to reject the unsolicited $69 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to ...More
October 8, 2010
Posted in News, Business
Anemia Study Changed Way Docs Prescribe ESAs

EXTON, Pa.—Recent clinical reports on erythropoietin-stimulating agents have changed the way nephrologists are prescribing anemia drugs, according to recent survey results from BioTrends Research ...More
April 27, 2010
Posted in News, Business, Clinical & Pharma, Practice Management
Use of AMAG’s Feraheme on the Rise

EXTON, Pa.— Six months after launching, the use of AMAG Pharmaceuticals' Feraheme is on the rise with 23 percent of nephrologists reporting use of the IV iron drug, according to new survey results from BioTrends Research Group. ...More
February 16, 2010
Posted in News, Business, Clinical & Pharma, Practice Management
Future Iron Treatments Shaped by New Payment Structures, Products

The choice of what iron product to use will be especially relevant with the bundled payment set to start in 2011. According to an August 2009 BioTrends report, dialysis clinic medical directors foresee the increased use of IV iron to spare the use of ESAs (such as Amgen’s ...More
January 29, 2010
Posted in Articles, Business, Clinical & Pharma, Practice Management
Many New ESRD Patients Haven’t Seen Nephrologist

WASHINGTON—In 2007, many patients starting end-stage renal disease therapy received no nephrologist care, dietary counseling or therapy with erythropoietin-stimulating agents prior to treatment, suggesting that the transition to ESRD is poor in the United States, according ...More
September 23, 2009
Posted in News, Business, Clinical & Pharma, Government & Regulation
Watson, GeneraMedix to Market Generic Ferrlecit

MORRISTOWN, N.J.—Watson Pharmaceuticals Inc. announced July 29 a license agreement with GeneraMedix Inc., for the exclusive U.S. marketing rights to a generic version of Ferrlecit, a drug indicated for the treatment of iron deficiency anemia in hemodialysis patients ...More
July 29, 2009
Posted in News, Business, Clinical & Pharma
Sanofi Pasteur to Produce New Influenza A(H1N1) Vaccine

WASHINGTON—The U.S. government has placed the first of what is expected to be a series of orders to Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, to commence production of a vaccine to help protect against the new influenza A(H1N1) virus. ...More
May 27, 2009
Posted in News, Clinical & Pharma, Government & Regulation